|
1
|
Jonasch E, Gao J and Rathmell WK: Renal
cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Poppel H, Becker F, Cadeddu JA, Gill
IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F,
Polascik TJ, et al: Treatment of localised renal cell carcinoma.
Eur Urol. 60:662–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanji N and Yokoyama M: Treatment of
metastatic renal cell carcinoma and renal pelvic cancer. Clin Exp
Nephrol. 15:331–338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sousa C, Duarte D, Silva-Lima B and
Videira M: Repurposing natural dietary flavonoids in the modulation
of cancer tumorigenesis: Decrypting the molecular targets of
naringenin, hesperetin and myricetin. Nutr Cancer. 74:1188–1202.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Manisha DS, Ratheesh AK, Benny S and
Presanna AT: Heterocyclic and non-heterocyclic arena of
monocarboxylate transporter inhibitors to battle tumorigenesis.
Chem Biol Drug Des. 102:1604–1617. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan N, Hu X, Zhou R, Li Y, Wu W and Liu
N: A Review on Dietary Flavonoids as Modulators of the Tumor
Microenvironment. Mol Nutr Food Res. 67:e22004352023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Felice MR, Maugeri A, De Sarro G, Navarra
M and Barreca D: Molecular pathways involved in the anti-cancer
activity of flavonols: A focus on myricetin and kaempferol. Int J
Mol Sci. 23:44112022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X, Jung Ji, Cho HJ, Lim DY, Lee HS,
Chun HS, Kwon DY and Park JH: Fisetin inhibits the activities of
cyclin-dependent kinases leading to cell cycle arrest in HT-29
human colon cancer cells. J Nutr. 135:2884–2890. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haddad AQ, Venkateswaran V, Viswanathan L,
Teahan SJ, Fleshner NE and Klotz LH: Novel antiproliferative
flavonoids induce cell cycle arrest in human prostate cancer cell
lines. Prostate Cancer Prostatic Dis. 9:68–76. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak
K, Sharma AK, Kumar M, Aggarwal V and Sandhu SS: Fisetin and
quercetin: Promising flavonoids with chemopreventive potential.
Biomolecules. 9:1742019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsieh MH, Tsai JP, Yang SF, Chiou HL, Lin
CL, Hsieh YH and Chang HR: Fisetin suppresses the proliferation and
metastasis of renal cell carcinoma through Upregulation of
MEK/ERK-Targeting CTSS and ADAM9. Cells. 8:9682019. View Article : Google Scholar
|
|
12
|
Si Y, Liu J, Shen H, Zhang C, Wu Y, Huang
Y, Gong Z, Xue J and Liu T: Fisetin decreases TET1 activity and
CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and
invasion of renal cancer stem cell. J Cell Mol Med. 23:1095–1105.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jafarzadeh S, Baharara J and Tehranipour
M: Apoptosis induction with combined use of cisplatin and fisetin
in cisplatin-resistant ovarian cancer cells (A2780). Avicenna J Med
Biotechnol. 13:176–182. 2021.PubMed/NCBI
|
|
14
|
Zhuo W, Zhang L, Zhu Y, Zhu B and Chen Z:
Fisetin, a dietary bioflavonoid, reverses acquired
Cisplatin-resistance of lung adenocarcinoma cells through
MAPK/Survivin/Caspase pathway. Am J Transl Res. 7:2045–2052.
2015.PubMed/NCBI
|
|
15
|
Nebenfuehr S, Kollmann K and Sexl V: The
role of CDK6 in cancer. Int J Cancer. 147:2988–2995. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang J, Han P, Qian J, Zhang S, Wang S,
Cao Q and Shao P: Knockdown of ALPK2 blocks development and
progression of renal cell carcinoma. Exp Cell Res. 392:1120292020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo Z, Jia H and Ge J: MiR-206 suppresses
proliferation and epithelial-mesenchymal transition of renal cell
carcinoma by inhibiting CDK6 expression. Hum Cell. 33:750–758.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo L, Wang D and Zhang Z: MiR-384
represses tumorigenesis by regulating CDK6 and predicts prognosis
of clear cell renal cell carcinoma. J BUON. 23:787–794.
2018.PubMed/NCBI
|
|
19
|
Pan H, Hong Y, Yu B, Li L and Zhang X:
miR-4429 Inhibits Tumor Progression and Epithelial-Mesenchymal
Transition Via Targeting CDK6 in Clear Cell Renal Cell Carcinoma.
Cancer Biother Radiopharm. 34:334–341. 2019.PubMed/NCBI
|
|
20
|
Sundarraj K, Raghunath A, Panneerselvam L
and Perumal E: Fisetin inhibits autophagy in HepG2 Cells via
PI3K/Akt/mTOR and AMPK Pathway. Nutr Cancer. 73:2502–2514. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farooqi AA, Naureen H, Zahid R, Youssef L,
Attar R and Xu B: Cancer chemopreventive role of fisetin:
Regulation of cell signaling pathways in different cancers.
Pharmacol Res. 172:1057842021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Fang L, Zang Y, Ren J and Xu Z:
CIP2A promotes proliferation, invasion and chemoresistance to
cisplatin in renal cell carcinoma. J Cancer. 9:4029–4038. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seo SH and Jeong GS: Fisetin inhibits
TNF-α-induced inflammatory action and hydrogen peroxide-induced
oxidative damage in human keratinocyte HaCaT cells through
PI3K/AKT/Nrf-2-mediated heme oxygenase-1 expression. Int
Immunopharmacol. 29:246–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chang PR, Liou JW, Chen PY, Gao WY, Wu CL,
Wu MJ and Yen JH: The neuroprotective effects of flavonoid fisetin
against corticosterone-induced cell death through modulation of
ERK, p38, and PI3K/Akt/FOXO3a-dependent pathways in PC12 cells.
Pharmaceutics. 15:23762023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lloyd A, Reeves F, Abu-Ghanem Y and
Challacombe B: Metastasectomy in renal cell carcinoma: Where are we
now? Curr Opin Urol. 32:627–633. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cayetano-Salazar L, Nava-Tapia DA,
Astudillo-Justo KD, Arizmendi-Izazaga A, Sotelo-Leyva C,
Herrera-Martinez M, Villegas-Comonfort S and Navarro-Tito N:
Flavonoids as regulators of TIMPs expression in cancer:
Consequences, opportunities, and challenges. Life Sci.
308:1209322022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alhaj-Suliman SO, Wafa EI and Salem AK:
Engineering nanosystems to overcome barriers to cancer diagnosis
and treatment. Adv Drug Deliv Rev. 189:1144822022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jafarzadeh E, Montazeri V, Aliebrahimi S,
Sezavar AH, Ghahremani MH and Ostad SN: Combined regimens of
cisplatin and metformin in cancer therapy: A systematic review and
meta-analysis. Life Sci. 304:1206802022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han Y, Wen P, Li J and Kataoka K: Targeted
nanomedicine in cisplatin-based cancer therapeutics. J Control
Release. 345:709–720. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ravula AR, Teegala SB, Kalakotla S,
Pasangulapati JP, Perumal V and Boyina HK: Fisetin, potential
flavonoid with multifarious targets for treating neurological
disorders: An updated review. Eur J Pharmacol. 910:1744922021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Simunkova M, Alwasel SH, Alhazza IM,
Jomova K, Kollar V, Rusko M and Valko M: Management of oxidative
stress and other pathologies in Alzheimer's disease. Arch Toxicol.
93:2491–2513. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kubina R, Krzykawski K, Kabała-Dzik A,
Wojtyczka RD, Chodurek E and Dziedzic A: Fisetin, a potent
anticancer flavonol exhibiting cytotoxic activity against
neoplastic malignant cells and cancerous conditions: A scoping,
comprehensive review. Nutrients. 14:26042022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maher P: Preventing and treating
neurological disorders with the flavonol fisetin. Brain Plast.
6:155–166. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J and Huang S: Fisetin inhibits the
growth and migration in the A549 human lung cancer cell line via
the ERK1/2 pathway. Exp Ther Med. 15:2667–2673. 2018.PubMed/NCBI
|
|
36
|
Ho CS, Grange RW and Joho RH: Pleiotropic
effects of a disrupted K+ channel gene: Reduced body weight,
impaired motor skill and muscle contraction, but no seizures. Proc
Natl Acad Sci USA. 94:1533–1538. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ying TH, Yang SF, Tsai SJ, Hsieh SC, Huang
YC, Bau DT and Hsieh YH: Fisetin induces apoptosis in human
cervical cancer HeLa cells through ERK1/2-mediated activation of
caspase-8-/caspase-3-dependent pathway. Arch Toxicol. 86:263–273.
2012. View Article : Google Scholar : PubMed/NCBI
|
